1
|
Ong WL, Allan Hupman M, Davidson M, Ruschin M, Detsky J, Liu S, Vesprini D, Loblaw A. Urethra contouring on computed tomography urethrogram versus magnetic resonance imaging for stereotactic body radiotherapy in prostate cancer. Clin Transl Radiat Oncol 2024; 45:100722. [PMID: 38234697 PMCID: PMC10792737 DOI: 10.1016/j.ctro.2023.100722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Revised: 12/24/2023] [Accepted: 12/30/2023] [Indexed: 01/19/2024] Open
Abstract
Accurate urethra contouring is critical in prostate SBRT. We compared urethra contouring on CT-urethrogram and T2-weighted MRI. The dice similarity coefficient, Jaccard index, Hausdorff distance and mean distance to agreement were evaluated. All four metrics indicate better agreement and less variability in urethra contouring on CT-urethrogram, compared to T2-weighted MRI.
Collapse
Affiliation(s)
- Wee Loon Ong
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada
- Department of Radiation Oncology, University of Toronto, Canada
- Alfred Health Radiation Oncology, Monash University, Melbourne, Australia
| | - M. Allan Hupman
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada
- Department of Radiation Oncology, University of Toronto, Canada
| | - Melanie Davidson
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada
- Department of Radiation Oncology, University of Toronto, Canada
| | - Mark Ruschin
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada
- Department of Radiation Oncology, University of Toronto, Canada
| | - Jay Detsky
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada
- Department of Radiation Oncology, University of Toronto, Canada
| | - Stanley Liu
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada
- Department of Radiation Oncology, University of Toronto, Canada
| | - Danny Vesprini
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada
- Department of Radiation Oncology, University of Toronto, Canada
| | - Andrew Loblaw
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada
- Department of Radiation Oncology, University of Toronto, Canada
- Department of Health Policy, Measurement and Evaluation, University of Toronto, Canada
| |
Collapse
|
2
|
Korsager AS, Carl J, Riis Østergaard L. Comparison of manual and automatic MR-CT registration for radiotherapy of prostate cancer. J Appl Clin Med Phys 2016; 17:294-303. [PMID: 27167285 PMCID: PMC5690943 DOI: 10.1120/jacmp.v17i3.6088] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Revised: 01/26/2016] [Accepted: 01/19/2016] [Indexed: 11/23/2022] Open
Abstract
In image‐guided radiotherapy (IGRT) of prostate cancer, delineation of the clinical target volume (CTV) often relies on magnetic resonance (MR) because of its good soft‐tissue visualization. Registration of MR and computed tomography (CT) is required in order to add this accurate delineation to the dose planning CT. An automatic approach for local MR‐CT registration of the prostate has previously been developed using a voxel property‐based registration as an alternative to a manual landmark‐based registration. The aim of this study is to compare the two registration approaches and to investigate the clinical potential for replacing the manual registration with the automatic registration. Registrations and analysis were performed for 30 prostate cancer patients treated with IGRT using a Ni‐Ti prostate stent as a fiducial marker. The comparison included computing translational and rotational differences between the approaches, visual inspection, and computing the overlap of the CTV. The computed mean translational difference was 1.65, 1.60, and 1.80 mm and the computed mean rotational difference was 1.51°, 3.93°, and 2.09° in the superior/inferior, anterior/posterior, and medial/lateral direction, respectively. The sensitivity of overlap was 87%. The results demonstrate that the automatic registration approach performs registrations comparable to the manual registration. PACS number(s): 87.57.nj, 87.61.‐c, 87.57.Q‐, 87.56.J‐
Collapse
|
3
|
Carl J, Sander L. Five-year follow-up using a prostate stent as fiducial in image-guided radiotherapy of prostate cancer. Acta Oncol 2015; 54:862-7. [PMID: 25539443 DOI: 10.3109/0284186x.2014.987355] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PURPOSE To report results from the five-year follow-up on a previously reported study using image-guided radiotherapy (IGRT) of localized or locally advanced prostate cancer (PC) and a removable prostate stent as fiducial. MATERIAL AND METHODS Patients with local or locally advanced PC were treated using five-field 3D conformal radiotherapy (3DRT). The clinical target volumes (CTV) were treated to 78 Gy in 39 fractions using daily on-line image guidance (IG). Late genito-urinary (GU) and gastro-intestinal (GI) toxicities were scored using the radiotherapy oncology group (RTOG) score and the common toxicity score of adverse events (CTC) score. Urinary symptoms were also scored using the international prostate symptom score (IPSS). RESULTS Median observation time was 5.4 year. Sixty-two of the 90 patients from the original study cohort were eligible for toxicity assessment. Overall survival, cancer-specific survival and biochemical freedom from failure were 85%, 96% and 80%, respectively at five years after radiotherapy. Late toxicity GU and GI RTOG scores≥2 were 5% and 0%. Comparing pre- and post-radiotherapy IPSS scores indicate that development in urinary symptoms after radiotherapy may be complex. CONCLUSIONS Prostate image-guided radiotherapy using a prostate stent demonstrated survival data comparable with recently published data. GU and GI toxicities at five-year follow-up were low and comparable to the lowest toxicity rates reported. These findings support that the precision of the prostate stent technique is at least as good as other techniques. IPSS revealed a complex development in urinary symptoms after radiotherapy.
Collapse
Affiliation(s)
- Jesper Carl
- Department of Medical Physics, Oncology, Aalborg University Hospital , Aalborg , Denmark
| | | |
Collapse
|
4
|
Korsager AS, Carl J, Østergaard LR. MR-CT registration using a Ni-Ti prostate stent in image-guided radiotherapy of prostate cancer. Med Phys 2014; 40:061907. [PMID: 23718598 DOI: 10.1118/1.4807087] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE In image-guided radiotherapy of prostate cancer defining the clinical target volume often relies on magnetic resonance (MR). The task of transferring the clinical target volume from MR to standard planning computed tomography (CT) is not trivial due to prostate mobility. In this paper, an automatic local registration approach is proposed based on a newly developed removable Ni-Ti prostate stent. METHODS The registration uses the voxel similarity measure mutual information in a two-step approach where the pelvic bones are used to establish an initial registration for the local registration. RESULTS In a phantom study, the accuracy was measured to 0.97 mm and visual inspection showed accurate registration of all 30 data sets. The consistency of the registration was examined where translation and rotation displacements yield a rotation error of 0.41° ± 0.45° and a translation error of 1.67 ± 2.24 mm. CONCLUSIONS This study demonstrated the feasibility for an automatic local MR-CT registration using the prostate stent.
Collapse
Affiliation(s)
- Anne Sofie Korsager
- Department of Health Science and Technology, Aalborg University, Aalborg 9220, Denmark.
| | | | | |
Collapse
|
5
|
Urethra sparing – potential of combined Nickel–Titanium stent and intensity modulated radiation therapy in prostate cancer. Radiother Oncol 2012; 103:256-60. [DOI: 10.1016/j.radonc.2011.11.015] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2011] [Revised: 11/20/2011] [Accepted: 11/22/2011] [Indexed: 11/21/2022]
|
6
|
Poulsen PR, Fledelius W, Keall PJ, Weiss E, Lu J, Brackbill E, Hugo GD. A method for robust segmentation of arbitrarily shaped radiopaque structures in cone-beam CT projections. Med Phys 2011; 38:2151-6. [PMID: 21626948 DOI: 10.1118/1.3555295] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE Implanted markers are commonly used in radiotherapy for x-ray based target localization. The projected marker position in a series of cone-beam CT (CBCT) projections can be used to estimate the three dimensional (3D) target trajectory during the CBCT acquisition. This has important applications in tumor motion management such as motion inclusive, gating, and tumor tracking strategies. However, for irregularly shaped markers, reliable segmentation is challenged by large variations in the marker shape with projection angle. The purpose of this study was to develop a semiautomated method for robust and reliable segmentation of arbitrarily shaped radiopaque markers in CBCT projections. METHODS The segmentation method involved the following three steps: (1) Threshold based segmentation of the marker in three to six selected projections with large angular separation, good marker contrast, and uniform background; (2) construction of a 3D marker model by coalignment and backprojection of the threshold-based segmentations; and (3) construction of marker templates at all imaging angles by projection of the 3D model and use of these templates for template-based segmentation. The versatility of the segmentation method was demonstrated by segmentation of the following structures in the projections from two clinical CBCT scans: (1) Three linear fiducial markers (Visicoil) implanted in or near a lung tumor and (2) an artificial cardiac valve in a lung cancer patient. RESULTS Automatic marker segmentation was obtained in more than 99.9% of the cases. The segmentation failed in a few cases where the marker was either close to a structure of similar appearance or hidden behind a dense structure (data cable). CONCLUSIONS A robust template-based method for segmentation of arbitrarily shaped radiopaque markers in CBCT projections was developed.
Collapse
Affiliation(s)
- Per Rugaard Poulsen
- Department of Oncology, Aarhus University Hospital, Nr Brogade 44, 8000 Aarhus C, Denmark.
| | | | | | | | | | | | | |
Collapse
|
7
|
Carl J, Nielsen J, Holmberg M, Larsen EH, Fabrin K, Fisker RV. Clinical results from first use of prostate stent as fiducial for radiotherapy of prostate cancer. Acta Oncol 2011; 50:547-54. [PMID: 21174520 DOI: 10.3109/0284186x.2010.541935] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PURPOSE A clinical feasibility study using a removable prostate stent as fiducial for image-guided radiotherapy (IGRT) of localized prostate cancer (PC). MATERIAL AND METHODS The study included patients with local or locally advanced PC. The clinical target volume (CTV) was outlined on magnetic resonance (MR) images co-registered to planning computer tomography (CT) images. Daily online IGRT was delivered using the stent as fiducial. Risk of migration was estimated using multiple MR. Acute urinary toxicity was scored using the international prostate symptom score (IPSS). Late gastro-intestinal (GI) and genito-urinary (GU) toxicity was scored using the Radio Therapy Oncology Group (RTOG) score, biochemical failure (BF) was defined as an elevation of prostate specific antigen (PSA) above nadir plus 2 ng/ml after radiotherapy. RESULTS One hundred men were enrolled in the study. Ninety completed radiotherapy with the stent as fiducial. No migration of the stent was seen, but three cases of dislocation of the stent to the bladder were observed. Acute urinary toxicity based on IPSS was comparable to toxicity in patients who had gold markers (GM) as fiducials. Removal of the stent was associated with a high frequency of urinary retention. Late GI and GU toxicity and BF were comparable to those of other studies, but longer observation time is needed. CONCLUSIONS This study reports the first clinical results of using a prostate stent as fiducial. No migration of the stent observed. Dislocation of the stent to the urinary bladder was observed in three cases, requiring removal of the stent and insertion of a new fiducial. Acute toxicity during radiotherapy evaluated from IPSS was comparable to toxicity in patients with GM. Removal of the stent was associated with a high frequency of post procedural urinary retention. Late toxicity and BF were comparable to those of other studies, though longer observation time is needed.
Collapse
Affiliation(s)
- Jesper Carl
- Department of Medical Physics, Department of Oncology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark.
| | | | | | | | | | | |
Collapse
|
8
|
Herrmann R, Carl J, Jäkel O, Bassler N, Petersen JBB. Investigation of the dosimetric impact of a Ni-Ti fiducial marker in carbon ion and proton beams. Acta Oncol 2010; 49:1160-4. [PMID: 20831508 DOI: 10.3109/0284186x.2010.505934] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
INTRODUCTION Fiducial markers based on a removable stent are currently used in image guided radiotherapy. Here it is investigated what the possible dosimetric impact of such a marker could be, if used in proton or carbon ion treatment. MATERIAL AND METHODS The simulations have been done using the Monte Carlo particle transport code FLUKA with its default hadron therapy settings. A 3 cm long stent is approximated in FLUKA by stacking hollow tori. To simulate realistic clinical conditions a field 5 × 5 cm has been used, delivering a 5 cm wide spread out Bragg peak located 5 cm deep for protons and carbon ions. For protons fields mimicking active and passive beam delivery have been investigated. The stent has been arranged perpendicular, turned 45 degrees, and parallel to the beam axis. RESULTS The position of the 95% dose level shifts for carbon ions 7 mm in proximal direction for the marker perpendicular to the beam and 8 mm if the stent is turned 45 degree for a 1 × 1 cm dose binning on the centre beam axis. For the case where the stent was parallel to beam direction the 95% dose level shifts 26 mm. For active delivered protons, the shift of the 95% dose level is less. The shift for a perpendicular arranged marker is 6 mm, for 45 degrees turned it is 7 mm. For the case where the stent was oriented parallel to the beam, the observed shift is 21 mm. Dose inhomogeneities caused by straggling effects occur only near the distal edge of the field. CONCLUSIONS The results of our investigations show that the Ni-Ti marker has a non negligible impact on the dose distributions for the used radiation types. However if the treatment plan rules out narrow angles between symmetry axis of the stent and the beam direction, this may be compensated.
Collapse
Affiliation(s)
- Rochus Herrmann
- Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark.
| | | | | | | | | |
Collapse
|
9
|
Jensen I, Carl J, Lund B, Larsen EH, Nielsen J. Radiobiological impact of reduced margins and treatment technique for prostate cancer in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP). Med Dosim 2010; 36:130-7. [PMID: 20488692 DOI: 10.1016/j.meddos.2010.02.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2009] [Revised: 02/09/2010] [Accepted: 02/18/2010] [Indexed: 02/07/2023]
Abstract
Dose escalation in prostate radiotherapy is limited by normal tissue toxicities. The aim of this study was to assess the impact of margin size on tumor control and side effects for intensity-modulated radiation therapy (IMRT) and 3D conformal radiotherapy (3DCRT) treatment plans with increased dose. Eighteen patients with localized prostate cancer were enrolled. 3DCRT and IMRT plans were compared for a variety of margin sizes. A marker detectable on daily portal images was presupposed for narrow margins. Prescribed dose was 82 Gy within 41 fractions to the prostate clinical target volume (CTV). Tumor control probability (TCP) calculations based on the Poisson model including the linear quadratic approach were performed. Normal tissue complication probability (NTCP) was calculated for bladder, rectum and femoral heads according to the Lyman-Kutcher-Burman method. All plan types presented essentially identical TCP values and very low NTCP for bladder and femoral heads. Mean doses for these critical structures reached a minimum for IMRT with reduced margins. Two endpoints for rectal complications were analyzed. A marked decrease in NTCP for IMRT plans with narrow margins was seen for mild RTOG grade 2/3 as well as for proctitis/necrosis/stenosis/fistula, for which NTCP <7% was obtained. For equivalent TCP values, sparing of normal tissue was demonstrated with the narrow margin approach. The effect was more pronounced for IMRT than 3DCRT, with respect to NTCP for mild, as well as severe, rectal complications.
Collapse
Affiliation(s)
- Ingelise Jensen
- Department of Medical Physics, Aalborg Hospital, University of Aarhus, Aalborg, Denmark.
| | | | | | | | | |
Collapse
|
10
|
Carl J, Nielsen J, Holmberg M, Højkjær Larsen E, Fabrin K, Fisker RV. A new fiducial marker for Image-guided radiotherapy of prostate cancer: clinical experience. Acta Oncol 2008; 47:1358-66. [PMID: 18618341 DOI: 10.1080/02841860802241972] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND A new fiducial marker for image guided radiotherapy (IGRT) based on a removable prostate stent made of Ni Ti has been developed during two previous clinical feasibility studies. The marker is currently being evaluated for IGRT treatment in a third clinical study. METHOD The new marker is used to co-register MR and planning CT scans with high accuracy in the region around the prostate. The co-registered MR-CT volumes are used for delineation of GTV before planning. In each treatment session the IGRT system is used to position the patient before treatment. The IGRT system use a stereo pair of kV images matched to corresponding Digital Reconstructed Radiograms (DRR) from the planning CT scan. The match is done using mutual gray scale information. The pair of DRR's for positioning is created in the IGRT system with a threshold in the Look Up Table (LUT). The resulting match provides the necessary shift in couch coordinates to position the stent with an accuracy of 1-2 mm within the planned position. RESULTS At the present time 39 patients have received the new marker. Of the 39 one has migrated to the bladder. Deviations of more than 5 mm between CTV outlined on CT and MR are seen in several cases and in anterior-posterior (AP), left-right (LR) and cranial-caudal (CC) directions. Intra-fraction translation movements up to +/- 3 mm are seen as well. As the stent is also clearly visible on images taken with high voltage x-rays using electronic portal images devices (EPID), the positioning has been verified independently of the IGRT system. DISCUSSION The preliminary result of an on going clinical study of a Ni Ti prostate stent, potentially a new fiducial marker for image guided radiotherapy, looks promising. The risk of migration appears to be much lower compared to previous designs.
Collapse
|
11
|
Poulsen PR, Fokdal L, Petersen J, Høyer M. Accuracy of image-guided radiotherapy of prostate cancer based on the BeamCath® urethral catheter technique. Radiother Oncol 2007; 83:25-30. [PMID: 17386952 DOI: 10.1016/j.radonc.2007.03.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2006] [Revised: 03/05/2007] [Accepted: 03/09/2007] [Indexed: 11/23/2022]
Abstract
BACKGROUND AND PURPOSE To examine the accuracy of the BeamCath urethral catheter technique for prostate localization during radiotherapy. MATERIALS AND METHODS Sixty-four patients were CT scanned twice with the BeamCath catheter, and once without the catheter. The catheter contains radiopaque fiducial markers for prostate visualization on setup images. It is held in place by a balloon inflated with air in the bladder. The repeated CT scans were co-registered and the relative shifts of the BeamCath isocenter fiducial, the prostate center-of-mass, and external skin markers were evaluated. The displacement of the BeamCath isocenter fiducial relative to its position at the planning CT scan was also determined on setup films for 53 consecutive patients (222 setup films). RESULTS The standard deviation (SD) of the prostate movement relative to the BeamCath isocenter fiducial was 0.9 mm in the left-right (LR), 2.8 mm in the cranial-caudal (CC), and 1.6 mm in the anteroposterior (AP) directions, respectively. When the balloon radius differed more than 1mm between the CT scans (14 of 64 cases) the SD in the CC direction increased to 4.5 mm. The SD of the prostate movement relative to the pelvic bone was 0.6 mm (LR), 2.4 mm (CC), and 2.8 mm (AP), while the prostate movement relative to external skin markers was considerably larger. Removal of the catheter resulted in a mean cranial prostate movement of 1.5mm relative to the pelvic bone. Caudal catheter displacements of 7-30 mm were observed in 5% of the setup films. In these cases, recatherization was necessary to obtain reliable prostate localization. CONCLUSIONS The BeamCath catheter technique markedly improved prostate localization in all directions when compared with skin markers. In the AP direction, the BeamCath technique was also superior to the use of bony structures. However, in the CC direction the catheter position was very vulnerable to changes in the balloon volume.
Collapse
|
12
|
Sodee DB, Sodee AE, Bakale G. Synergistic Value of Single-Photon Emission Computed Tomography/Computed Tomography Fusion to Radioimmunoscintigraphic Imaging of Prostate Cancer. Semin Nucl Med 2007; 37:17-28. [PMID: 17161036 DOI: 10.1053/j.semnuclmed.2006.07.002] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The rationale on which positron emission tomography/computed tomography (PET/CT) imaging is based, combining the functional features of PET with the anatomic detail of CT, provides many advantages that are easily transferable to single-photon emission computed tomography (SPECT)/CT imaging. Our efforts have focused on applying fused SPECT/CT imaging to identify prostate cancer and its metastasis and recurrence through radioimmunoscintigraphy (RIS). This application of RIS to imaging prostate cancer requires 2 key components: (1) a well-defined target associated with the cancer and (2) a "magic bullet" to seek that target. A well-characterized RIS target for prostate cancer is prostate-specific membrane antigen, or PSMA, and finding the bullet to seek this target with high sensitivity and specificity has been the focus of intensive study for nearly two decades. One of the candidate bullets developed is capromab pendetide, which is a monoclonal antibody that seeks PSMA. This antibody is commercially available as ProstaScint, which can be labeled with indium-111 to localize prostate cancer via SPECT imaging. In the course of applying fused SPECT/CT ProstaScint imaging to more than 800 prostate cancer cases, numerous refinements to our protocol have evolved that are aimed at staging the cancer with utmost accuracy. In addition to optimizing the localization of prostate cancer and its metastasis, these refinements also have been extended toward guiding both the implantation of radioactive seeds in brachytherapy and in other types of radiation therapy which is illustrated through 5 case reports. Progress in the therapeutic targeting of PSMA is also being actively explored, which has more universal ramifications because PSMA is found in the neovasculature of other types of cancers.
Collapse
Affiliation(s)
- D Bruce Sodee
- Department of Radiology, Division of Nuclear Medicine, University Hospitals of Cleveland and Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
| | | | | |
Collapse
|
13
|
Carl J, Nielsen H, Nielsen J, Lund B, Larsen EH. Automated detection of a prostate Ni-Ti stent in electronic portal images. Med Phys 2006; 33:4600-5. [PMID: 17278812 DOI: 10.1118/1.2369466] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Planning target volumes (PTV) in fractionated radiotherapy still have to be outlined with wide margins to the clinical target volume due to uncertainties arising from daily shift of the prostate position. A recently proposed new method of visualization of the prostate is based on insertion of a thermo-expandable Ni-Ti stent. The current study proposes a new detection algorithm for automated detection of the Ni-Ti stent in electronic portal images. The algorithm is based on the Ni-Ti stent having a cylindrical shape with a fixed diameter, which was used as the basis for an automated detection algorithm. The automated method uses enhancement of lines combined with a grayscale morphology operation that looks for enhanced pixels separated with a distance similar to the diameter of the stent. The images in this study are all from prostate cancer patients treated with radiotherapy in a previous study. Images of a stent inserted in a humanoid phantom demonstrated a localization accuracy of 0.4-0.7 mm which equals the pixel size in the image. The automated detection of the stent was compared to manual detection in 71 pairs of orthogonal images taken in nine patients. The algorithm was successful in 67 of 71 pairs of images. The method is fast, has a high success rate, good accuracy, and has a potential for unsupervised localization of the prostate before radiotherapy, which would enable automated repositioning before treatment and allow for the use of very tight PTV margins.
Collapse
Affiliation(s)
- Jesper Carl
- Department of Medical Physics, Aalborg Hospital, University of Aarhus, Aalborg, Denmark.
| | | | | | | | | |
Collapse
|
14
|
Krause M, Zips D, Thames HD, Kummermehr J, Baumann M. Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother Oncol 2006; 80:112-22. [PMID: 16916560 DOI: 10.1016/j.radonc.2006.07.017] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2006] [Accepted: 07/19/2006] [Indexed: 12/24/2022]
Abstract
The combination of molecular-targeted agents with irradiation is a highly promising avenue for cancer research and patient care. Molecular-targeted agents are in themselves not curative in solid tumours, whereas radiotherapy is highly efficient in eradicating tumour stem cells. Recurrences after high-dose radiotherapy are caused by only one or few surviving tumour stem cells. Thus, even if a novel agent has the potential to kill only few tumour stem cells, or if it interferes in mechanisms of radioresistance of tumours, combination with radiotherapy may lead to an important improvement in local tumour control and survival. To evaluate the effects of novel agents combined with radiotherapy, it is therefore necessary to use experimental endpoints which reflect the killing of tumour stem cells, in particular tumour control assays. Such endpoints often do not correlate with volume-based parameters of tumour response such as tumour regression and growth delay. This calls for radiotherapy specific research strategies in the preclinical testing of novel anti-cancer drugs, which in many aspects are different from research approaches for medical oncology.
Collapse
Affiliation(s)
- Mechthild Krause
- Department of Radiation Oncology, Medical Faculty Carl Gustav Carus, University of Technology Dresden, Germany
| | | | | | | | | |
Collapse
|